CINDER BIOLOGICAL, INC.
BERKELEY, CA · CIK 0001774944 · Biotech · Private
Ultra-stable Archaeal proteases for protein digestion in proteomics workflows
- Grants
- $3.7M
- 5 awards
- Sector median: 1
- Raised
- $100K
- 1 Form D · Jun 2019
- 88 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 6
- 1 granted · 5 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201520162017201820192020202120222023
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | National Science Foundation · Phase II · SBIR Phase II: Improving food safety using hyper-stable enzyme cleaning products | $899,893 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel ultra-stable enzymes and methods for proteomics | $150,000 | |
| Private capital raised | Form D · SEC | $100,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel ultra-stable enzymes and methods for proteomics | $922,905 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel ultra-stable enzymes and methods for proteomics | $728,715 | |
| Federal grant | Department of Agriculture · **awards Issued Prior To January 20, 2025, Were Funded Under Previous Administrations And May Not Reflect The Priorities And Policies Of The Current Administration.** Cleaning And Sanitation Are Critical Operations In All Food Processing Facilities To Avoid Foodborne Illness And Economically Disastrous Product Recalls. Currently, Antimicrobial Synthetic Chemicals Are Central To Cleaning And Sanitation Approaches In Food Processing. These Chemicals Contact Work Surfaces And Utensils And Can Be In | $999,987 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2657 | Sustained Therapeutics Inc. | — | $100K |
| 2658 | GALIBRA NEUROSCIENCE, INC. | — | $100K |
| 2659 | Blue Marlin Therapeutics, Inc. | — | $100K |
| 2660 | CINDER BIOLOGICAL, INC. | — | $100K |
| 2661 | Nano Pharmasolutions Inc. | — | $75K |
| 2662 | Normunity | — | — |
| 2663 | UNIVERSAL CELLS, INC. | — | $60K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Jill FussDirector · Executive Officer · Promoter
- Steven YannoneDirector · Executive Officer · Promoter
Patents
- Methods For Rapidly Digesting Biopolymers With Ultrastable Enzymes For Mass Spectrometry-based Analysesgranted
- Enzymatic Cleaning And Sanitizing Compositions And Methods Of Using The Sameapplication
- Methods For Rapidly Digesting Biopolymers With Ultrastable Enzymes For Mass Spectrometry-based Analysesapplication
- Methods For Rapidly Digesting Biopolymers With Ultrastable Enzymes For Mass Spectrometry-based Analysesapplication
- Enzymatic Cleaning And Sanitizing Compositions And Methods Of Using The Sameapplication
- Enzymatic Cleaning And Sanitizing Compositions And Methods Of Using The Sameapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.